Sep 14, 2025
1:00 PM2:00 PM
Poster Session
P318 - BODY COMPOSITION AS A PROGNOSTIC MARKER IN PATIENTS WITH LUNG CANCER
P318
BODY COMPOSITION AS A PROGNOSTIC MARKER IN PATIENTS WITH LUNG CANCER
E. S. C. Carvalho1,*, M. Mamede2, N. B. de Pinho3
1oncology, IPSEMG, 2Anatomy and imaging, UFMG, Belo Horizonte, 3Brazilian Society of Oncological Nutrition, Rio de Janeiro, Brazil
Rationale: ung cancer is often diagnosed late, reducing survival. Objective to evaluate body composition as a prognostic marker in patients with lung cancer.
Methods: Twenty-four lung cancer patients diagnosed between January 2015 and June 2017 who underwent computed tomography (CT) at a public hospital in Belo Horizonte, Minas Gerais, Brazil, were retrospectively evaluated. A CT slice at L3 was used to calculate body composition using SliceOmatic 5.0 software. Skeletal muscle index and muscle fat infiltration (myosteatosis) were assessed. Sarcopenia was defined as a muscle index for men ≤52.4 cm2/m2 and for women ≤38.5 cm2/m2. ROC analysis was performed to predict death. Cutoff values were analyzed by Kaplan-Meier and Log-rank.
Results: The mean age was 67.5 years, and 62.5% were male. Seventeen (68%) died during the follow-up period. Nineteen (79.2%) had sarcopenia. The mean survival time after the first computed tomography scan was 553.6 ± 479.6 days. Myosteatosis with a cutoff value of 5.475% (AUC = 0.672, sensitivity of 76.5% and specificity of 71.4%, p = 0.193) showed good results, but did not reach statistical significance. Considering the cutoff value for myosteatosis, there was a significant difference in survival among patients, with a Log Rank of 14.144 (p = 0.0001).
Conclusion: Patients with lung cancer had a high prevalence of sarcopenia and those with myosteatosis above 5.475% had lower survival.Conclusion: Patients with lung cancer had a high prevalence of sarcopenia and those with myosteatosis above 5.475% had lower survival.
References: Mourtzakis M et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008.
Prado CM et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast can et acer patients receiving capecitabine treatment. Clin Cancer Res. 2009.
Disclosure of Interest: None declared